The inclusion of CD38 monoclonal antibodies (mAbs) in autologous stem-cell transplantation (ASCT) induction regimens has been associated with more patients with newly diagnosed multiple myeloma (NDMM) achieving deeper responses and higher rates of minimal residual disease-negativity. However, the impact of CD38 mAbs on haemopoietic stem-cell mobilization remains unclear, with some clinical trials reporting reduced stem-cell yields and increased plerixafor use following CD38 mAb induction therapy and real-world analyses reporting conflicting results. The aim of this study was to analyse the impact of CD38 mAb-based induction on total stem-cell yield in patients with NDMM undergoing ASCT in a real-world setting.

Clinical characteristics and outcomes can differ markedly in patients with non-transplant-eligible newly diagnosed multiple myeloma (NTENDMM) according to frailty. Three frailty subgroups have been proposed: frail-byage- alone (>80 years, no comorbidities or impairments in activities of daily living); frail-by-impairments (≤80 years, with comorbidities and/or impairments in activities of daily living); and ultra-frail (>80 years, with comorbidities and/or impairments in activities of daily living). The aim of this study was to examine the impact of frailty subtype on overall survival (OS) in a large group of patients with NTE-NDMM.

Elderly, frail patients with multiple myeloma have a lower tolerance of standard treatment with lenalidomide and dexamethasone and worse outcomes than younger, fitter patients, in part because of dexamethasone toxicity. The aim of this study was to compare the efficacy and safety of a dexamethasone-sparing regimen based on lenalidomide and daratumumab versus standard lenalidomide and dexamethasone in frail patients with multiple myeloma.

Individuals with plasmacytomas that are non-contiguous with bone marrow (true extramedullary myeloma) have a high risk of disease progression or relapse. In the phase 1 RedirecTT- 1 study, dual-antigen targeting with the anti-GPRC5D (G-protein-coupled receptor, class C, group 5, member D) agent talquetamab plus the anti-B-cell maturation antigen teclistamab led to a greater and more durable response than either agent alone among patients with triple-classexposed relapsed or refractory multiple myeloma, including true extramedullary myeloma. The aim of this study was to evaluate the efficacy and safety of talquetamab plus teclistamab solely in patients with drugresistant, true extramedullary myeloma.